-
Vanderbilt-Discovered Compound Advances to Phase 1 Clinical Trial as a Promising New Treatment for Schizophrenia
Neumora Therapeutics, Inc. has announced the launch of a Phase 1 clinical study evaluating NMRA-861 in healthy adult participants and adults with stable schizophrenia. -
Connecting Research to Real-World Solutions: Karl Zelik's HeroWear Journey
Karl Zelik, a Vanderbilt biomechanical engineer, turned academic research into HeroWear, a company making soft exosuits that reduce back strain and injuries for workers. HeroWear has grown into a global solution that improves safety, comfort, and quality of life for thousands, showing the power of…